Resistant Hypertension - 2019 Pipeline Insight Report: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Apr 1, 2019--The “Resistant Hypertension - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Resistant Hypertension development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the Report
Reasons to Buy
Key Topics Covered
1. Report Introduction
2. Resistant Hypertension Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fsbd6w/resistant?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005775/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 04/01/2019 02:17 PM/DISC: 04/01/2019 02:17 PM